Pulmonx Corp Net Worth
Pulmonx Corp Net Worth Breakdown | LUNG |
Pulmonx Corp Net Worth Analysis
Pulmonx Corp's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pulmonx Corp's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pulmonx Corp's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pulmonx Corp's net worth analysis. One common approach is to calculate Pulmonx Corp's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pulmonx Corp's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pulmonx Corp's net worth. This approach calculates the present value of Pulmonx Corp's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pulmonx Corp's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pulmonx Corp's net worth. This involves comparing Pulmonx Corp's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pulmonx Corp's net worth relative to its peers.
Enterprise Value |
|
To determine if Pulmonx Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulmonx Corp's net worth research are outlined below:
| Pulmonx Corp is way too risky over 90 days horizon | |
| Pulmonx Corp appears to be risky and price may revert if volatility continues | |
| Pulmonx Corp has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 83.79 M. Net Loss for the year was (56.39 M) with profit before overhead, payroll, taxes, and interest of 62 M. | |
| Pulmonx Corp currently holds about 162.09 M in cash with (31.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.35. | |
| Pulmonx Corp has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Analyzing Spectral Medical Pulmonx |
Pulmonx Corp Quarterly Good Will |
|
Pulmonx Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulmonx Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulmonx Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Pulmonx Corp Target Price Consensus
Pulmonx target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pulmonx Corp's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Pulmonx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pulmonx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pulmonx Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPulmonx Corp Target Price Projection
Pulmonx Corp's current and average target prices are 7.97 and 11.58, respectively. The current price of Pulmonx Corp is the price at which Pulmonx Corp is currently trading. On the other hand, Pulmonx Corp's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Pulmonx Corp Target Price
Know Pulmonx Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmonx Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmonx Corp backward and forwards among themselves. Pulmonx Corp's institutional investor refers to the entity that pools money to purchase Pulmonx Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 768.4 K | State Street Corp | 2024-12-31 | 759.3 K | Braidwell Lp | 2024-12-31 | 752.5 K | Franklin Resources Inc | 2024-12-31 | 576.3 K | Kent Lake Pr Llc | 2024-12-31 | 418.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 408 K | D. E. Shaw & Co Lp | 2024-12-31 | 392.8 K | Pura Vida Investments, Llc | 2024-12-31 | 387.2 K | Northern Trust Corp | 2024-12-31 | 372.7 K | Fmr Inc | 2024-12-31 | 5.9 M | Primecap Management Company | 2024-12-31 | 5.5 M |
Follow Pulmonx Corp's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 310.01 M.Market Cap |
|
Project Pulmonx Corp's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.35) | (0.36) | |
| Return On Equity | (0.66) | (0.62) |
When accessing Pulmonx Corp's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pulmonx Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulmonx Corp's profitability and make more informed investment decisions.
Evaluate Pulmonx Corp's management efficiency
Pulmonx Corp has return on total asset (ROA) of (0.2055) % which means that it has lost $0.2055 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5526) %, meaning that it created substantial loss on money invested by shareholders. Pulmonx Corp's management efficiency ratios could be used to measure how well Pulmonx Corp manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.37. The current Return On Capital Employed is estimated to decrease to -0.44. At this time, Pulmonx Corp's Debt To Assets are most likely to slightly decrease in the upcoming years. The Pulmonx Corp's current Asset Turnover is estimated to increase to 0.54, while Total Current Assets are projected to decrease to roughly 88.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.19 | 2.30 | |
| Tangible Book Value Per Share | 2.13 | 2.24 | |
| Enterprise Value Over EBITDA | (4.35) | (4.57) | |
| Price Book Value Ratio | 3.09 | 1.58 | |
| Enterprise Value Multiple | (4.35) | (4.57) | |
| Price Fair Value | 3.09 | 1.58 | |
| Enterprise Value | 251.1 M | 238.6 M |
Leadership effectiveness at Pulmonx Corp is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 3.1627 | Revenue | Quarterly Revenue Growth 0.233 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmonx Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmonx Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmonx Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pulmonx Corp Corporate Filings
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 19th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 4th of February 2025 Other Reports | ViewVerify |
Pulmonx Corp Earnings per Share Projection vs Actual
Pulmonx Corp Corporate Management
| David Lehman | General Secretary | Profile | |
| Geoffrey Rose | Chief Officer | Profile | |
| Lauren Cristina | Vice Administration | Profile | |
| John McKune | VP Controller | Profile | |
| Sri Radhakrishnan | Chief Officer | Profile | |
| Mehul Joshi | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Revenue Per Share | Quarterly Revenue Growth 0.233 | Return On Assets | Return On Equity |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.